Certificate PL-26-00161 · Cartalax 20 mg Pen · lot PL-2610-039 · branded for Epic Wholesalers LLC -dba-Epic Peptides Lab
VerifyCertificate page
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · Lot release
www.epicpeptideslab.com
Certificate no.
PL-26-00161
Verification key
FA86RQWR
Scan or enter both at
prymalab.net/testing/verify

Certificate of Analysis · Lot release · Issued for Epic Wholesalers LLC -dba-Epic Peptides Lab

Cartalax 20 mg Pen

Lot PL-2610-039 · Solution · Label claim 20 mg/mL
Tested in-house by PrymaLab
In-house analytical result,
not an independent third-party test
Lot / batch number
PL-2610-039
Date made
2026-10-01
Date of analysis
2026-10-02
Date issued
2026-10-16
Retest / expiry
2028-10-01
Units in lot / sampled
290 / 2
Storage
—
Certificate type
Lot COA, 2 pages
Compound
Cartalax
Ala-Glu-Asp (AED; T-31); Khavinson cartilage peptide bioregulator
CAS number
n/a
Molecular formula
C12H19N3O8
Theoretical mass (avg.)
333.30 Da
Sequence
AED
Purity · RP-HPLC, area %
99.54%
Specification ≥ 99.0% • main peak at 10.50 min
Identity · Observed Mass
333.28 Da
Theoretical 333.30 Da • −0.02 Da (60 ppm)
Overall conclusion
PASS
Meets every specification for the tests performed
TestMethodSpecificationResultConclusion
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da333.28 DaPASS
PurityRP-HPLC, UV 214 nm, area%≥ 99.0%99.54%PASS
Largest impurityRP-HPLC, area%≤ 1.0%0.21% (RT 11.40)PASS
Assay (label claim)Assay vs label claim19–21 mg/mL20.29 mg/mLPASS
Bacterial endotoxinLAL, kinetic≤ 5.0 EU/mg0.289 EU/mgPASS
SterilityUSP <71>, 14-dayNo growthNo growthPASS

1HPLC chromatogram

Data file: PL-2610-039-HPLC.raw · Column C18, 150 × 4.6 mm · UV 214 nm
0.01%0.1%1%10%100%8910111213Retention time (min) · stick height = area % (log scale)99.54% · 10.50 min0.05% †0.21% †0.20% †
Peak plot drawn from the integrated peak table (area %, log scale); it is not the instrument trace, which is retained in PL-2610-039-HPLC.raw. † Nominal reference retention time for the assigned impurity; the main-peak RT is observed in this lot.
Epic Wholesalers LLC -dba-Epic Peptides Lab
Epic Wholesalers LLC -dba-Epic Peptides Lab
Certificate of Analysis · continued
Cartalax 20 mg Pen · Lot PL-2610-039 · Certificate PL-26-00161
Lot PL-2610-039
Method, peak table and approval

2HPLC method · PL-2610-039-HPLC.raw

Instrument
Waters Alliance e2695
Data System
Empower 3
Detector
UV absorbance
Detection Wavelength
214 nm
Column
C18, 150 × 4.6 mm, 3.5 µm
Mobile Phase A
0.1% TFA in water
Mobile Phase B
0.1% TFA in MeCN
Gradient
5–95% B over 25 min (linear)
Flow Rate
1.0 mL/min
Column Temperature
40 °C
Injection Volume
10 µL

3Gradient program

Time (min)% A% B
0.0955
25.0595

4Peak table

PeakRT (min)AreaArea %
19.20 †—0.05
210.50—99.54
311.40 †—0.21
412.00 †—0.20
Total—100.00
Peaks: 1 deamidation product; 2 main peak (Cartalax); 3 isoaspartate (isoasp) variant; 4 truncated sequence · Area % from the integrated peak table (absolute areas are not part of the lot-release export) · † nominal reference RT for the assigned impurity · Purity = main peak area ÷ total integrated area × 100, to two decimals; main peak shaded.

5Identity by mass spectrometry

Instrument
Waters SQD
Ionization / Mode
ESI, positive
Reference m/z (charge)
334.31 (M+H)+
Deconvoluted Mass
333.28 Da
Theoretical Mass
333.30 Da
Difference
−0.02 Da (60 ppm)
Data File
PL-2610-039-MS.d
Acceptance
Within ± 1.0 Da

6Additional tests

TestPerformed byDateReport / file
Assay vs label claimPrymaLab Analytical2026-10-02—
Endotoxin (LAL, kinetic)PrymaLab Analytical2026-10-02—
Sterility (USP <71>, day-14 read-out)PrymaLab Analytical2026-10-16—
A test with no row here was not performed on this lot. Outside-laboratory reports, when used, are attached and named below.

7Review and approval

D. Reynolds
Analyst · performed the testing
Date: 2026-10-16
S. Calloway
Reviewer · checked against raw data
Date: 2026-10-16
M. Phelps
Lab Director · approved for release
Date: 2026-10-16